A 6.4% share price pop on Friday offered Novo Nordisk investors a rare moment of relief, but the Danish drugmaker’s year-to-date scoreboard remains ugly. The stock closed at €35.09 in Frankfurt, still nursing a roughly 21% decline since January and trading nearly 50% below its 52-week peak of €70.13. The relative strength index, at 17.8, screams oversold — a technical backdrop that amplified the latest bounce.
The catalyst came from two separate clinical readouts, neither of which involved the blockbuster weight-loss franchise that made Novo a household name.
A Teenage Diabetes First
On Friday, the market’s attention was grabbed by the PIONEER TEENS trial. The Phase 3a study enrolled 132 adolescents aged 10 to 17 with type 2 diabetes and tested oral semaglutide against placebo. After 26 weeks, the treatment group saw HbA1c drop by 0.83 percentage points more than the control arm. The safety profile matched what has already been documented in adults.
Novo Nordisk plans to file for regulatory label expansions with both the FDA and the European Medicines Agency in the second half of 2026. If approved, oral semaglutide would become the first GLP-1 therapy cleared for pediatric use — a meaningful commercial and clinical milestone.
Sickle Cell Breakthrough Adds Pipeline Depth
Just days earlier, on April 20, the company unveiled Phase 3 data for Etavopivat, an oral pill targeting sickle cell disease. The drug hit both primary endpoints. Patients experienced 27% fewer vaso-occlusive crises, and the median time to the first such event stretched to 38.4 weeks versus barely 21 weeks in the placebo group. Nearly half of treated patients recorded a significant hemoglobin boost.
Novo has already secured fast-track designation from the FDA and intends to submit marketing applications in the second half of 2026. The candidate represents a deliberate push beyond the GLP-1 umbrella — a diversification play that analysts are watching closely.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Washington Clouds the Outlook
Clinical progress aside, the stock’s structural headwinds are formidable. Semaglutide is slated to fall under Medicare price negotiations starting in 2027. Novo has pushed back legally and spent over $8 million on lobbying last year alone, but the outcome remains uncertain.
Management’s own guidance for 2026 forecasts a currency-adjusted revenue decline of between 5% and 13%. Citi recently trimmed its price target to 275 Danish kroner from 309 kroner, reflecting the constrained near-term visibility.
Meanwhile, the competitive landscape is shifting. In India, patent protection for Wegovy and Ozempic has lapsed, and roughly 40 generic manufacturers now offer the active ingredients at an estimated $36 per month — less than half the original price. Novo has responded with price adjustments but plays down the threat publicly.
In the US, Amazon is muscling into the GLP-1 distribution chain, and Eli Lilly is advancing its own oral obesity therapies. Yet some institutional investors are leaning into the weakness: M&T Bank Corp recently boosted its Novo Nordisk stake by more than 300%, to nearly 317,000 shares.
A Buyback in the Background
Since February, Novo has been executing a share repurchase program worth up to 15 billion Danish kroner. By mid-April, it had already scooped up roughly 12 million shares. The buyback provides a modest floor, but it is fighting against a tide of pricing pressure and margin uncertainty.
The next concrete test for market confidence will come when the company files its pediatric and sickle cell applications later this year. Until then, Novo Nordisk remains caught between genuine pipeline promise and the harsh arithmetic of US payer politics.
Ad
Novo Nordisk Stock: Buy or Sell?! New Novo Nordisk Analysis from April 25 delivers the answer:
The latest Novo Nordisk figures speak for themselves: Urgent action needed for Novo Nordisk investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from April 25.
Novo Nordisk: Buy or sell? Read more here...
